SyntheticMR is proud to share the results of a newly published multicenter clinical study in the American Journal of Neuroradiology, demonstrating the diagnostic equivalence—and potential advantages—of SyMRI using the 3D-QALAS method compared to conventional 3D MRI in routine clinical neuroimaging.
Health Technology Insights: Viz.ai Forms Alliance to Boost AI Cancer Diagnosis and Care
The peer-reviewed study, available here, evaluated a large and diverse patient population across multiple imaging centers. The findings confirmed that 3D synthetic MRI using SyMRI matched conventional MRI in sensitivity, specificity, and diagnostic accuracy. Notably, SyMRI received even higher ratings for image quality.
“These results underscore the value of SyMRI in real-world clinical practice,” said Johanna Norén, Acting CEO of SyntheticMR. “With diagnostic performance on par with conventional imaging—and with added benefits in workflow efficiency and quantitative imaging—SyMRI has the potential to enhance diagnostic confidence while streamlining MRI protocols.”
Health Technology Insights: bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
The study highlights SyMRI’s ability—particularly in 3D—to deliver quantitative, multi-contrast images in a single, fast scan without compromising image quality, making it a strong candidate for advancing scalable and standardized neuroimaging practices.
This clinical evidence further strengthens SyntheticMR’s mission to redefine MRI efficiency, bringing the power of objective, quantitative imaging into routine clinical use.
Health Technology Insights: Clairity: First FDA-Approved AI for Breast Cancer Prediction
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
